SCHEMBL923923

SCHEMBL923923

CCCCn1ccnc(S(=O)(=O)Cc2ccc(Cl)cc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
BRD4 O60885 1/20 0.41
NPC1 O15118 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
TXNRD1 Q16881 1/20 0.36
TLR8 Q9NR97 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GRM2 Q14416 1/20 0.35
KCNH2 Q12809 1/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923550 0.93 RECQL (0.43) RECQLBRD4ALDH1A1KMT2ANPSR1
SCHEMBL923366 0.88 RECQL (0.41) RECQLBRD4ALDH1A1KMT2ANPSR1
SCHEMBL924230 0.86 PLCG1 (0.42) NPC1ALDH1A1POLBKMT2AMAPT
SCHEMBL922918 0.86 PDE4A (0.40) BRD4NPC1ALDH1A1POLBKMT2A
SCHEMBL925933 0.82 RECQL (0.46) RECQLBRD4NPC1TSHRALDH1A1
SCHEMBL923336 0.81 GRM2 (0.39) BRD4NPC1TSHRALDH1A1POLB
SCHEMBL923811 0.81 BRD4 (0.41) RECQLBRD4GRM2KCNH2LMNA
SCHEMBL923790 0.81 NPSR1 (0.39) BRD4NPC1TSHRALDH1A1POLB
SCHEMBL924370 0.80 ALDH1A1 (0.45) BRD4TSHRALDH1A1NPSR1MAPT
SCHEMBL922938 0.80 PDE1A (0.40) TSHRALDH1A1POLBKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US claimed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP claimed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US claimed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US claimed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US claimed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
EP-2250156-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-11-17 EP disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES GLP1R, GPR119, IAPP RECQL 1494/4885BRD4 2509/4885NPC1 3529/4885
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes GLP1R, IAPP, INSR RECQL 1607/4885BRD4 2323/4885NPC1 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.